Long-Term Stability of Alzheimer's Disease Biomarker Proteins in Cerebrospinal Fluid

The quantitative analysis of peptides in human cerebrospinal fluid (CSF) has become an important step in the early diagnosis of dementia, e. g., Alzheimer's disease. In search of new biomarkers for early detection and differential diagnosis of chronic neurodegenerative diseases, biobanking and long-term storage of human samples is increasingly important. The German Dementia Competence Network (DCN) has accomplished one of the largest biomaterial banks in this field, comprising CSF from several hundreds of patients. Since little is known about long-term stability of biomarker proteins in frozen CSF, we investigated the reliability of quantitative analysis in a total of 56 CSF samples that had been frozen for up to six years. Here, we compare a second quantitative analysis of A beta(40), A beta(42), and the total-tau protein after several years of storage at -80 degrees C with initial results obtained within six months after lumbar puncture. The second analysis was done using standard ELISAs or the newly developed Mesocale System. We found that regarding A beta(42) and total-tau, the results highly correlate with correlation coefficients of c = 0.73 and c = 0.82 respectively, while for A beta(40) the correlation coefficient was lower (c = 0.53), suggesting that A beta(40) is more vulnerable to degradation. We conclude that the quantitative analysis of the concentration of A beta(42), as well as for total-tau, in CSF in samples that have been stored for years is reliable. The determination of these biomarkers and potentially new biomarkers in CSF samples stored in large biomaterial banks assembled over many years is feasible.